Bob Grant, Jef Akst, and Tracy Vence | Dec 23, 2016 | 5 min read
This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.